

November 07, 2024

To,

Listing Department

National Stock Exchange Of India Limited,

Exchange Plaza,

Bandra Kurla Complex,

Bandra (East), Mumbai- 400 051

NSE Symbol. VIJAYA

To,

The Corporate Relations Department

BSE Limited,

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

Mumbai - 400 001

BSE Scrip Code. 543350

Dear Sir/Madam

Subject: Press Release on Q2 & FY 2025 Results

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the "Press Release on Q2 & FY 2025 Results" being issued by the Company.

Please take the information on record.

Thanking You.

Yours Faithfully For **Vijaya Diagnostic Centre Limited**

Hansraj Singh Company Secretary & Compliance Officer M. No. F11438

Encl.: As above



Regd. Office - 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India

Vijaya Diagnostic Centre Limited announces Q2 FY25 results, with an impressive 31.8% YoY revenue growth, fueled by higher volumes and contributions from both existing and new centres

Hyderabad, November 7, 2024: Vijaya Diagnostic Centre Limited (NSE: VIJAYA, BSE: 543350), one of India's leading integrated diagnostic chains, has announced its financial results for the quarter ended 30th Sep 2024.

Note:

Acquisition (PH Diagnostic Centre Private Limited, Pune): PH has become a wholly-owned subsidiary effective from 21st December 2023. Consequently, its financials have been consolidated from 21st December 2023 in the last financial year FY 2023-24.

Hence, the consolidated operational and financial figures of Q1 FY 25, Q2 FY25 and H1 FY 25 below include PH, unless otherwise stated.

Consolidated Financial Performance:

Particulars (Rs. Mn)	Q2FY25	Q2FY24	YoY %	Q1FY25	QoQ %
Revenue from Operations	1,829.5	1,388.6	31.8%	1,562.2	17.1%
Revenue from Operations (excl PH)	1,707.5	1,388.6	23.0%	1,448.2	17.9%
EBITDA	759.8	573.7	32.5%	612.4	24.1%
EBITDA Margin (%)	41.5%	41.3%	22 Bps	39.2%	233 Bps
Profit after Tax (PAT)	419.4	333.2	25.9%	313.5	33.8%
PAT Margin (%)	22.9%	24.0%	-107 Bps	20.1%	286 Bps

Operational Highlights:

In millions, unless otherwise specified

Particulars	Q2FY25	Q2FY24	YoY %	Q1FY25	QoQ %
Total Tests	3.95	3.03	30.5%	3.38	16.9%
Total Footfall	1.13	0.91	24.3%	0.96	17.5%
Tests per Footfall	3.49	3.32	5.0%	3.51	-0.5%
Total Tests (excl PH)	3.69	3.03	22.1%	3.14	17.5%
Total Footfall (excl PH)	1.08	0.91	18.2 %	0.92	17.5%
Avg realization per test (Rs)	463	459	1.0%	462	0.2%
Avg realization per Footfall (Rs)	1,616	1,525	6.0%	1,621	-0.3%
Wellness share %	13.7%	12.9%	6.2%	13.4%	2.3%



Key Developments:

Penetrating Tier II Territory in Andhra Pradesh: Unveiled a Standalone Hub Centre in Ongole - August 2024

- In line with our strategic momentum aimed at expanding into Tier II and Tier III cities within key geographies, we are pleased to announce the establishment of a new hub facility in Ongole, Andhra Pradesh.
- This development represents a significant milestone in Vijaya's growth plan as we expand into the
 diagnostic space within this promising region. The new facility is equipped with state-of-the-art
 technology, featuring an automated laboratory and advanced diagnostic equipment, including a 3T
 MRI and a 160-slice cardiac CT.

Inaugurating a state-of-the-art hub in Nizamabad, Telangana, on 8th Nov 2024

- Continuing our strategic expansion into Tier II cities within key geographies, we are excited to announce the launch of a new hub facility in Nizamabad.
- This state of-the-art centre houses advanced equipment like a 3T MRI, CT Scan and an automated lab.
- With our 'All Under One Roof' model, we are setting a new benchmark for diagnostic services in the Nizamabad district.

Venturing into Bangalore City

- Entering Bangalore, a potential Tier1 market through organic route.
- Bangalore is largely dominated by semi-branded, integrated chains, each with a presence in only 2 to 4 locations across the city.
- The market holds significant potential for us, and we plan to create a dense network in the years to

Commenting on the performance Ms. Suprita Reddy, MD & CEO said

"I'm excited to announce another key milestone in our growth journey. We have delivered a robust quarter, achieving an impressive 31.8% YoY revenue growth, of which 23.0% was organic. This strong performance was driven primarily by volume, with contributions coming from both our existing and newly launched centres.

I'm also delighted to share that we successfully launched operations at our Hub center in Ongole this August, and the response in the first two months has been very promising. In addition, we are excited to begin operations at our new state-of-the-art facility in Nizamabad tomorrow. This center features cuttingedge technologies, including a 3T MRI, CT scan, an automated lab, and a range of basic radiology modalities.

We've also upgraded our spoke centre in Gurgaon, transforming it into a fully equipped hub with the addition of MRI and CT machines. This enhancement enables us to provide a complete range of services, from basic blood tests to advanced imaging, all conveniently available under one roof at our Gurgaon centre."

-END-



About Us:

Vijaya Diagnostic Centre Limited (Vijaya), is one of India's largest integrated diagnostic chains with a dominant presence in South and Western India. Vijaya provides a one-stop solution for pathology and radiology investigations through an extensive operational network spanning 147 diagnostic centres and 22 reference laboratories in 24 cities and towns spread across Telangana, Andhra Pradesh, Maharashtra, Karnataka, NCR and Kolkata. The company offers comprehensive diagnostic services ranging from basic pathology to high-end radiology.

Corporate Identification No: L85195TG2002PLC039075

Regd. Office: 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.

For more information, please visit www.vijayadiagnostic.com OR contact:

Mr. Siva Rama Raju, CFA

Head - Strategy & Investor Relations Vijaya Diagnostic Centre Limited

Tel: +91 99485 95555

Email: sivaramaraju.v@vijayadiagnostic.in

ir@vijayadiagnostic.in

DISCLAIMER:

Certain statements that may be made in the press release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. Vijaya Diagnostic Centre Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.